Introduction 1
Since the first human cases in 1997 in Hong Kong (5, 29, 33) , highly pathogenic 2 H5N1 avian influenza A viruses have been circulating among avian species and have 3 spread throughout Asia, Europe, and Africa with sporadic transmission to humans and 4 high mortality (http://www.who.int/csr/disease/avian_influenza/en/). Since the seasonal 5 influenza vaccine does not elicit effective immunity against H5N1 influenza viruses, we 6 must rely on antiviral drugs to combat these deadly viruses. the NA protein (VN1203-N294S virus), were generated by using reverse genetics (13) as 13 described previously (19, 22) Effect of the NA N294S substitution on pathogenicity in mice. To evaluate the 10 pathogenicity of H5N1 virus possessing the NA N294S substitution in mice, four animals 11 were intranasally infected with NA N294S-possessing HN30408 (HN30408-N294S 12 virus). As controls, we used the oseltamivir-sensitive (HN30408 virus) and the highly 13 resistant (HN30408-H274Y virus) clones of HN30408. The remaining seven genes of 14 these two control viruses were identical to those of HN30408-N294S virus. While 15 HN30408 and HN30408-H274Y viruses showed high and limited lethality in mice, 16 respectively, the lethality of HN30408-N294S virus in this model was moderate (Fig. 1) . 17
The mouse lethal dose 50% (MLD 50 ) of HN30408, HN30408-H274Y, and HN30408-18 N294S viruses was 20, >10 6 , and 3.2 x 10 4 PFU, respectively. These results indicate that 19 the NA N294S substitution attenuates the H5N1 virus in mice, although the degree of this 20 attenuation is lower than that caused by the NA H274Y substitution. 21
Effect of the NA N294S substitution on pathogenicity and oseltamivir-1 sensitivity in ferrets. To evaluate the pathogenicity and oseltamivir-sensitivity of H5N1 2 virus possessing the NA N294S substitution in ferrets, three animals per group were 3 intranasally infected with either HN30408 or HN30408-N294S virus. The infected ferrets 4
were then mock-treated or treated with oseltamivir phosphate. Body temperature and 5 weight were monitored daily for ten days. In addition, nasal washes were collected on 6 days 1, 3, 5, 7, and 9 pi to determine virus titer. During these experiments, one of the 7 HN30408 virus-infected, mock-treated ferret died on day 5 pi. Viruses were recovered 8 from the various organs of the dead ferrets (Table 1) , demonstrating the high virulence of 9 the oseltamivir-sensitive HN30408 virus. 10
In mock-treated ferrets, the oseltamivir-sensitive HN30408 virus exhibited higher 11 pathogenicity [e.g, substantial increase in body temperature ( Fig. 2A) and severe loss in 12 body weight (Fig. 2E) ] compared to the oseltamivir-resistant HN30408-N294S virus. In 13 nasal washes, higher titers of virus were recovered from the HN30408 virus-infected 14 ferrets than from the HN30408-N294S virus-infected ferrets from days 1-7; we found a 15 statistically significant difference in titers on days 1 (P = 0.048, Student's t-test), 3 (P = 16 0.0006), and 5 (P = 0.0048) pi ( weight of the HN30408 virus-infected ferrets (Figs. 2G and 2H ), whereas no substantial 10 differences were observed in body temperature and weight of the HN30408-N294S virus-11 infected ferrets due to the limited pathogenicity of HN30408-N294S virus (Figs. 2C, 2D , 12 2G, and 2H). Virological analysis revealed that zanamivir inhibited the replication of 13 both HN30408 and HN30408-N294S viruses (Fig. 3B) . These results indicate that the 14 NA N294S substitution does not affect the zanamivir-sensitivity of the H5N1 virus in 15 ferrets. One of the HN30408 virus-infected, mock-treated ferret died on day 4 pi due to 16 systemic infection (Table 1) HN30408 and its oseltamivir-resistant variants (Figs. 2-3 ) (23), we found no statistically 7 significant differences in body temperature (Fig. 4A ), weight loss (Fig. 4B) , or virus titers 8 in organs (Fig. 4C) among the VN1203-, VN1203-H274Y-, and VN1203-N294S viruses-9 infected animals, indicating that both VN1203-H274Y and VN1203-N294S viruses are 10 comparable to their parental VN1203 virus in terms of ferret pathogenicity. These results 11 suggest that the impact of the NA H274Y and N294S substitutions on the pathogenicity 12 of human H5N1 viruses varies depending on the virus strain. 13
In this study, we assessed the effect of the NA N294S mutation that was found in 14 viruses in oseltamivir-treated H5N1 influenza patients on the replication and 15 pathogenicity of human H5N1 viruses and on the efficacy of NA inhibitors in mouse and 16 ferret models. In the background of HN30408 virus, the NA N294S mutation 17 substantially impaired the efficacy of oseltamivir (but not zanamivir) in ferrets (Fig. 3)  18 and in vitro (23) and decreased virus replication and pathogenicity in mice (Fig. 1) and  19 ferrets (Figs. 2A, 2C , 2E, 2G, and 3) compared to that of the oseltamivir-sensitive 20 counterpart. By contrast, consistent with the mouse data (19, 22, 32), the ferret 21 pathogenicity of VN1203 virus was not significantly altered by introducing the NA 22 N294S substitution (Fig. 4) . Recently, Ilyushina et al. reported that the NA N294S 23 substitution conferred a moderate level of oseltamivir-resistance and increased virus 1 virulence in ferrets by using an A/turkey/15/06 (H5N1)-based recombinant mutant 2 possessing the NA N294S mutation (18). These results suggest that the effect of the NA 3 N294S substitution on the oseltamivir sensitivity, replication, and ferret pathogenicity of 4 human H5N1 viruses differs depending on the virus strain. Importantly, VN1203 virus 5 possessing the NA N294S substitution was a potential killer of ferrets (Table 2) , 6 underscoring the importance of monitoring the emergence of the NA N294S substitution 7 in circulating H5N1 viruses. 8
At present, several NA inhibitors are available, such as laninamivir or peramivir. 9
Laninamivir, also known as CS-8958, is effective against oseltamivir-resistant viruses (19, 10 21, 31), although, like zanamivir, this inhaled drug is not appropriate for severe or infant 11 patients. By contrast, peramivir is an intravenous NA inhibitor that can be given to 12 patients who cannot be treated with inhaled drugs (28); however, some oseltamivir-13 resistant viruses are cross-resistant to peramivir (12) . To minimize the likelihood of 14 emergence of NA inhibitor-resistant viruses and effectively treat patients infected with 15 such viruses, we should consider stockpiling a variety of NA inhibitors. a One each of the wild-type VN1203-, VN1203-H274Y-, and VN1203-N294S viruses-infected 10 ferrets died on days 7, 8, and 8 post-infection, respectively. Virus recovered from the various 11 organs of these ferrets was titrated by use of plaque assays in MDCK cells. 12
